Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Vitiligo
NCT04971200Phase 1Completed
- Sponsor
- Premier Specialists
- Start
- Sep 2021
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tildrakizumab in Vitiligo, sponsored by Premier Specialists. Primary endpoints: Vitiligo Area Scoring Index at 24 weeks, Vitiligo Extent Score at 24 weeks and 1 more. Started Sep 2021; status: completed.
02
Drugs
tildrakizumab
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT04971200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971200.